PT  - JOURNAL ARTICLE
AU  - KAREL SMETANA, JR.
AU  - DANIEL ROSEL
AU  - JAN BRÁBEK
TI  - Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
AID  - 10.21873/invivo.12135
DP  - 2020 Sep 01
TA  - In Vivo
PG  - 3027--3028
VI  - 34
IP  - 5
4099  - http://iv.iiarjournals.org/content/34/5/3027.short
4100  - http://iv.iiarjournals.org/content/34/5/3027.full
SO  - In Vivo2020 Sep 01; 34
AB  - The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.